Ascend (Drug Discovery)
$42.5M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Ascend (Drug Discovery) is currently valued at $150.9M as of November 12, 2024. The company has raised a total of $194.3M in funding.
Capital Efficiency
With a capital efficiency ratio of 0.78x, Ascend (Drug Discovery) has achieved a valuation that is 0.78 times the total capital raised. This metric indicates room for improvement in capital deployment.
Investment Perspective
Ascend (Drug Discovery)'s valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Ascend (Drug Discovery) Worth in 2025?
As of 2025, Ascend (Drug Discovery) is valued at $150.9M, based on the company's Early Stage VC funding round in November 12, 2024. This valuation positions Ascend (Drug Discovery) as one of the leading private companies in the sector.
Ascend (Drug Discovery) Valuation History
Ascend (Drug Discovery)'s funding history demonstrates steady growth and investor confidence.
How Ascend (Drug Discovery) Valuation is Determined
Private company valuations like Ascend (Drug Discovery)'s are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Ascend (Drug Discovery) Valuation FAQs
Is Ascend (Drug Discovery) profitable?
Ascend (Drug Discovery) has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Ascend (Drug Discovery)'s valuation compare to competitors?
Ascend (Drug Discovery) is valued at $150.9M, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Ascend (Drug Discovery) IPO?
Ascend (Drug Discovery) has not announced plans for an initial public offering. Until an IPO, investors can access Ascend (Drug Discovery) shares through secondary market platforms.